These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 33268125)

  • 41. Florid Foreign Body-type Giant Cell Response to Keratin Is Associated With Improved Overall Survival in Patients Receiving Preoperative Therapy for Esophageal Squamous Cell Carcinoma.
    Chen W; Zhao L; Agoston A; White A; Mazzola E; Boyle PJ; Deshpande V; Hornick JL; Bueno R; Bass AJ; Enzinger P; Mamon H; Redston M; Patil DT
    Am J Surg Pathol; 2021 Dec; 45(12):1648-1660. PubMed ID: 34469333
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Failure patterns after adjuvant chemoradiotherapy following endoscopic resection for superficial esophageal squamous cell carcinoma.
    Ikawa T; Ishihara R; Konishi K; Morimoto M; Hirata T; Kanayama N; Yamamoto S; Matsuura N; Wada K; Hayashi K; Ogawa K; Teshima T
    Cancer Med; 2019 Aug; 8(10):4547-4554. PubMed ID: 31222974
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Association between the thoroughness of the histopathological examination and survival in patients with esophageal squamous cell carcinoma who achieve pathological complete response after chemoradiotherapy.
    Chiu CH; Chen WH; Wen YW; Yeh CJ; Chao YK; Chang HK; Tseng CK; Liu YH
    Dis Esophagus; 2016 Aug; 29(6):634-41. PubMed ID: 26175202
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prognostic impact of sterilized lymph nodes in esophageal squamous cell carcinomas after neoadjuvant chemoradiotherapy.
    Zhong J; Wang K; Fang S; Fu J
    Eur J Surg Oncol; 2021 Dec; 47(12):3074-3080. PubMed ID: 34023168
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Nodal Downstaging of Esophageal Squamous Cell Carcinoma after Neoadjuvant Chemoradiotherapy: Survival Analysis if ypN0 Is Achieved.
    Tang H; Tan L; Wang H; Shen Y; Yin J
    J Gastrointest Surg; 2020 Jul; 24(7):1469-1476. PubMed ID: 31346888
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PATHOLOGIC COMPLETE RESPONSE (YPT0 YPN0) AFTER CHEMOTHERAPY AND RADIOTHERAPY NEOADJUVANT FOLLOWED BY ESOPHAGECTOMY IN THE SQUAMOUS CELL CARCINOMA OF THE ESOPHAGUS.
    Andreollo NA; Beraldo GC; Alves IPF; Tercioti-Junior V; Ferrer JAP; Coelho-Neto JS; Lopes LR
    Arq Bras Cir Dig; 2018 Dec; 31(4):e1405. PubMed ID: 30539980
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response.
    Blackham AU; Yue B; Almhanna K; Saeed N; Fontaine JP; Hoffe S; Shridhar R; Frakes J; Coppola D; Pimiento JM
    J Surg Oncol; 2015 Nov; 112(6):597-602. PubMed ID: 26394724
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Prognostic Relevance of Lymph Node Regression After Neoadjuvant Chemoradiation for Esophageal Cancer.
    Philippron A; Bollschweiler E; Kunikata A; Plum P; Schmidt C; Favi F; Drebber U; Hölscher AH
    Semin Thorac Cardiovasc Surg; 2016 Summer; 28(2):549-558. PubMed ID: 28043475
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Risk Factors for Recurrence in Esophageal Squamous Cell Carcinoma Without Pathological Complete Response After Trimodal Therapy.
    Kurokawa T; Hamai Y; Emi M; Ibuki Y; Yoshikawa T; Ohsawa M; Hirohata R; Okada M
    Anticancer Res; 2020 Aug; 40(8):4387-4394. PubMed ID: 32727767
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Genome-wide and size-based cell-free DNA indices as predictive biomarkers for locally advanced esophageal squamous cell carcinoma treated with preoperative or definitive chemoradiotherapy.
    Kim EJ; Im HS; Lee J; Cho EH; Kim YH; Kim HR; Kim JH; Park SR
    Curr Probl Cancer; 2021 Jun; 45(3):100685. PubMed ID: 33342577
    [TBL] [Abstract][Full Text] [Related]  

  • 51. ASO Author Reflections: Exploring the Best Parameter for Lymph Node Assessment in Patients with Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemoradiotherapy.
    Huang X; Tan L
    Ann Surg Oncol; 2024 Feb; 31(2):899-900. PubMed ID: 38006528
    [No Abstract]   [Full Text] [Related]  

  • 52. Serum Cytokines Correlate with Pretreatment Body Mass Index-adjusted Body Weight Loss Grading and Cancer Progression in Patients with Stage III Esophageal Squamous Cell Carcinoma Undergoing Neoadjuvant Chemoradiotherapy Followed by Surgery.
    Pan YP; Kuo HC; Lin JY; Chou WC; Chang PH; Ling HH; Yeh KY
    Nutr Cancer; 2024; 76(6):486-498. PubMed ID: 38680010
    [TBL] [Abstract][Full Text] [Related]  

  • 53. ypN0 in Patients With Definitive cN-positive Status After Preoperative Treatment Is a Prognostic Factor in Esophageal Cancer.
    Yoshida T; Nishino T; Goto M; Inoue S; Fujiwara S; Takizawa H; Tangoku A; Uehara H; Bando Y
    Anticancer Res; 2022 Jan; 42(1):195-203. PubMed ID: 34969725
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Analysis of SPARC and TUBB3 as predictors for prognosis in esophageal squamous cell carcinoma receiving nab-paclitaxel plus cisplatin neoadjuvant chemotherapy: a prospective study.
    Gong L; Mao W; Chen Q; Jiang Y; Fan Y
    Cancer Chemother Pharmacol; 2019 Apr; 83(4):639-647. PubMed ID: 30643929
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Do We Need to Add Postoperative Radiotherapy in Patients Undergoing Trimodality Therapy for Esophageal Squamous Cell Carcinoma with Positive Lymph Nodes Disease?
    Huang PM; Hsu FM; Lin CC; Hsu CH; Cheng JC; Lee JM
    Dig Surg; 2018; 35(2):104-110. PubMed ID: 28675905
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Distribution of residual tumors in esophageal squamous cell carcinoma after neoadjuvant PD-1 blockade combined with chemotherapy.
    Jiang D; Song Q; Tang H; Shi P; Zhang X; Liu Y; Wang H; Deng M; Huang J; Su J; Xu C; Tan L; Hou Y
    Front Oncol; 2023; 13():1067897. PubMed ID: 36925921
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Supraclavicular and/or celiac lymph node metastases from thoracic esophageal squamous cell carcinoma did not compromise survival following neoadjuvant chemoradiotherapy and surgery.
    Cho WK; Oh D; Ahn YC; Shim YM; Zo JI; Sun JM; Ahn MJ; Park K
    Oncotarget; 2017 Jan; 8(2):3542-3552. PubMed ID: 27682879
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Outcomes of patients with esophageal squamous cell carcinoma who achieved a pathological complete response in the primary lesion by neoadjuvant treatment: a Japanese nationwide cohort study.
    Okamura A; Watanabe M; Okui J; Matsuda S; Takemura R; Kawakubo H; Kakeji Y; Kono K; Kitagawa Y; Takeuchi H
    Esophagus; 2024 Jan; 21(1):2-10. PubMed ID: 37999900
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Pattern of tumor regression after neoadjuvant chemoimmunotherapy for esophageal squamous cell carcinoma.
    Li B; Wang Y; Yu H; Chen H; Sun Y; Hu H; Zhang Y; Xiang J; Li Y; Chen H
    J Thorac Dis; 2023 Oct; 15(10):5517-5524. PubMed ID: 37969295
    [TBL] [Abstract][Full Text] [Related]  

  • 60. How Many Nodes Need to be Removed to Make Esophagectomy an Adequate Cancer Operation, and Does the Number Change When a Patient has Chemoradiotherapy Before Surgery?
    Yeung JC; Bains MS; Barbetta A; Nobel T; DeMeester SR; Louie BE; Orringer MB; Martin LW; Reddy RM; Schlottmann F; Molena D
    Ann Surg Oncol; 2020 Apr; 27(4):1227-1232. PubMed ID: 31605332
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.